Show simple item record

Authordc.contributor.authorBellei, Mónica 
Authordc.contributor.authorFoss, Francine M. 
Authordc.contributor.authorShustov, Andrei 
Authordc.contributor.authorHorwitz, Steven M. 
Authordc.contributor.authorMarcheselli, Luigi 
Authordc.contributor.authorKim, Won Seog 
Authordc.contributor.authorCabrera, María Elena 
Authordc.contributor.authorDlouhy, Iván 
Authordc.contributor.authorNagler, Arnon 
Authordc.contributor.authorAdvani, Ranjana H. 
Authordc.contributor.authorPesce, Emanuela Anna 
Authordc.contributor.authorKo, Young-Hyeh 
Authordc.contributor.authorMartínez, Virginia 
Authordc.contributor.authorMontoto, Silvia 
Authordc.contributor.authorChiattone, Carlos 
Authordc.contributor.authorMoskowitz, Alison 
Authordc.contributor.authorSpina, Michele 
Authordc.contributor.authorBiasoli, Irene 
Authordc.contributor.authorManni, Martina 
Authordc.contributor.authorFederico, Massimo 
Cita de ítemdc.identifier.citationHaematologica, 103(7), 03 julio 2018, 1191-1197 pp.es_ES
Abstractdc.description.abstractThis analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of 937 patients who received first-line treatment, 436 (47%) were identified as refractory and 197 (21%) as relapsed. Median time from the end of treatment to relapse was 8 months (range 2-73). Overall, 75 patients (8%) were consolidated with bone marrow transplantation, including 12 refractory and 22 relapsed patients. After a median follow up of 38 months (range 1-96 months) from documentation of refractory/relapsed disease, 440 patients had died. The median overall survival (OS) was 5.8 months; 3-year overall survival rates were 21% and 28% for refractory and relapsed patients, respectively (P<0.001). Patients receiving or not salvage bone marrow transplantation had a 3-year survival of 48% and 18%, respectively (P<0.001). In a univariate Cox regression analysis, refractory disease was associated with a higher risk of death (HR=1.43, P=0.001), whereas late relapse (>12 months, HR 0.57, P=0.001) and salvage therapy with transplantation (HR=0.36, P<0.001) were associated with a better OS. No difference was found in OS with respect to histology. This study accurately reflects outcomes for patients treated according to standards of care worldwide. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression. Patients with chemotherapy sensitive disease who relapsed after more than 12 months might benefit from consolidation bone marrow transplantation.es_ES
Patrocinadordc.description.sponsorshipFondazione Cassa di Risparmio di Modena, Modena, Italy; Associazione Angela Serra per la Ricerca sul Cancro, Modena, Italy; Fondazione Italiana Linfomi (FIL), Alessandria, Italy; Allos Therapeutics, Inc., Westminster, CO, USA; AIRC (Associazione Italiana per la Ricerca sul Cancro) 5x1000: 10007; NIH/NCI CCSG: P30 CA008748; Spectrum Pharmaceuticals Inc., Henderson, NV, USA.es_ES
Publisherdc.publisherFerrata Storti Foundationes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile*
Link to Licensedc.rights.uri*
Keywordsdc.subjectresponse criteriaes_ES
Títulodc.titleThe outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Projectes_ES
Document typedc.typeArtículo de revista
Indexationuchile.indexArtículo de publicación ISIes_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile